Rituximab versus splenectomy in persistent or chronic adult primary immune thrombocytopenia: an adjusted comparison of mortality and morbidity.
about
Treatment Options for Primary Autoimmune Hemolytic Anemia: A Short Comprehensive ReviewBacterial Infections Following Splenectomy for Malignant and Nonmalignant Hematologic DiseasesThromboembolism in adults with primary immune thrombocytopenia: a systematic literature review and meta-analysis.Need for an improved vaccination rate in primary immune thrombocytopenia patients exposed to rituximab or splenectomy. A nationwide population-based study in France.Treatment of refractory ITP and Evans syndrome by haematopoietic cell transplantation: is it indicated, and for whom?Corticosteroid Risk Function of Severe Infection in Primary Immune Thrombocytopenia Adults. A Nationwide Nested Case-Control Study.Rituximab salvage therapy in adults with immune thrombocytopenia: retrospective study on efficacy and safety profiles.Long-term outcome following splenectomy for chronic and persistent immune thrombocytopenia (ITP) in adults and children : Splenectomy in ITP.Long-term results of splenectomy in adult chronic immune thrombocytopenia.Infections in non-splenectomized persistent or chronic primary immune thrombocytopenia adults: risk factors and vaccination effect.Emerging drugs for immune thrombocytopenia (ITP).Clinical Practice Updates in the Management Of Immune Thrombocytopenia.Splenectomy vs. rituximab as a second-line therapy in immune thrombocytopenic purpura: a single center experience.Low Dose Rituximab in Chronic ITP: Still an Option in Resource Limited Settings.Cost-consequence model comparing eltrombopag and romiplostim in pediatric patients with chronic immune thrombocytopeniaCost-consequence model comparing eltrombopag versus romiplostim for adult patients with chronic immune thrombocytopenia
P2860
Q26773178-BB1074E3-7E52-4A7F-86AB-EE2CD9C4D5F1Q26778773-614CF1A3-5F79-475F-86F4-4DBAED7B32A2Q30250259-B5DC848F-ADCB-4B3F-B525-3EB5A5D37373Q33419605-0B21A35B-5F47-4BFD-9DD8-7868149328A9Q33424451-7EE71D0B-B8E5-4A12-92B6-14F6FBBB1DEEQ33427488-2687B336-0DD4-47AA-8728-09C0F676F8D0Q33431198-89B731EA-757F-41BA-AA6B-D79BE92BAF2BQ33433585-34C0B752-4142-4883-A7C1-E0C1D92890D3Q33436100-01E776BE-FF1A-4C47-BE0C-CC806E344354Q33438334-A353D92D-14F9-49D8-BDA1-077A4DF26356Q33439789-90B8953A-8745-4D6A-98A1-5C8597D3412BQ47161464-1509301F-17EB-4ADC-8C7E-A8281E239FFDQ47998948-FAC31CA3-AC63-4C1E-936E-7954077753C5Q50092881-DCBAD00D-A724-4968-A2ED-A0729E667D41Q59125749-B0BBAB18-C24B-4B19-BEAE-260570BD6B14Q59135184-095B98D8-A68C-4FE3-8053-AE2B401A5112
P2860
Rituximab versus splenectomy in persistent or chronic adult primary immune thrombocytopenia: an adjusted comparison of mortality and morbidity.
description
2013 nî lūn-bûn
@nan
2013 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Rituximab versus splenectomy i ...... on of mortality and morbidity.
@ast
Rituximab versus splenectomy i ...... on of mortality and morbidity.
@en
type
label
Rituximab versus splenectomy i ...... on of mortality and morbidity.
@ast
Rituximab versus splenectomy i ...... on of mortality and morbidity.
@en
prefLabel
Rituximab versus splenectomy i ...... on of mortality and morbidity.
@ast
Rituximab versus splenectomy i ...... on of mortality and morbidity.
@en
P2093
P2860
P356
P1476
Rituximab versus splenectomy i ...... on of mortality and morbidity.
@en
P2093
Agnès Sommet
Daniel Adoue
Guillaume Moulis
Hélène Derumeaux
Laurent Sailler
P2860
P356
10.1002/AJH.23580
P577
2013-09-30T00:00:00Z